

SEP 08 2009

Application No. 10/580,108
Response to Office Action of 7/07/2009
Page 2 of 16

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

Claim 1. (Currently Amended) A targeted glycoconjugate comprising a bioactive agent and a targeting compound, wherein the bioactive agent and targeting compound are joined by a modified UDP galactose acetyl group (UDP-GalNAc) saccharide compound, and wherein the modified UDP-GalNAc saccharide compound comprises a ketone galactose and a reactive functional group attached to the C2 position of the galactose ring.

Claim 2. (Original) The glycoconjugate of claim 1 wherein the bioactive agent comprises a polypeptide; releasing factor; releasing factor inhibitor; carbohydrate; nucleic acid; vaccine; anti-antibiotic; antiviral agent; anti-fungal agent; analgesics anesthetic; anti-helminthic; anti-arthritis agent; anti-asthmatic agent; anticonvulsant; antidepressant; anti-diabetic agent; anti-diarrheal; anticonvulsant; antihistamine; anti-inflammatory agent; toxin, anti-migraine preparation; anti-nauseant; anticancer agent; anti-parkinsonism drug; ; anti-psychotic; antipyretic; anti-spasmodic; anti-cholinergic; sympathomimetic; xanthine derivative; cardiovascular agent; anti-arrhythmic; anti-hyperlipidemic agent; anti-hypertensive; diuretic; anti-diuretic; receptor agonist; receptor antagonist; vasodilator; central nervous system stimulant; vasoconstrictor; cough and cold preparation; enzyme inhibitor; hormone; hypnotic; agent; muscle relaxant; parasympatholytic; central nervous system stimulant; diuretic; hypnoticsleukotriene inhibitor; mitotic inhibitor; muscle relaxant; genetic material; psychostimulant; sedative; anabolic agent; vitamin; herbal remedy; anti-metabolic agent; anxiolytic; attention deficit disorder (ADD) drug; attention deficit hyperactivity disorder (ADHD) drug; neuroleptic agent; or tranquilizer.

Claim 3. (Original) The glycoconjugate of claim 1, wherein the targeting compound comprises a glycoprotein, glycolipid or carbohydrate.

BOS2 752775.1

Application No. 10/580,108
Response to Office Action of 7/07/2009
Page 3 of 16

Claim 4. – 42. (Cancelled)

Claim 43. (Original) A pharmaceutical composition comprising the glycoconjugate of claim 1 and a pharmaceutically acceptable carrier.

Claim 44. (Previously Presented) A kit comprising the glycoconjugate of claim 1 and instructions for use in a therapeutic or diagnostic method.

Claim 45. (Original) A glycoconjugate according to claim 1 for use in medical therapy.

Claims 46 - 48. (Cancelled)

Claim 49. (Currently Amended) A targeted glycoconjugate comprising a bioactive agent and a targeting compound, wherein the targeting compound is an antibody, and wherein the bioactive agent and targeting compound are joined by a modified UDP galactose acetyl group (UDP-GalNAc) saccharide compound, and wherein the UDP-GalNAc saccharide compound comprises ~~galactose~~ and a reactive functional group attached to the C2 position of the galactose ring, wherein the reactive functional group is a ketone group.

BOS2 752775.1